Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide B

Disclosures: The authors declare no competing financial interests.

Contributions: M.K.K., D.K., R.V. and J.J.L. contributed equally to this study. J.E.C., M.D.B., and J.J.L conceived and guided the research. J.E.C., M.D.B., J.J.L., M.K.K., and DK were involved in designing of the experiments, analysis of the data, and interpretation of the results, and participated in writing the manuscript. J.J.L and R.V. and M.D.B. prepared the samples of FD-895 used within this program. M.K.K, D.K, and H.J performed experiments; L.R., E.G., T.J.K. and J.E.C. provided patient samples, and patient clinical and laboratory data.